Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCP 122721 hydrochloride is a high affinity NK1 antagonist (pIC50 = 9.8). Suppresses recruitment of immunocytes in respiratory syncytial virus (RSV)-infected rats after capsaicin stimulation. Also blocks substance P-induced excitation of locus ceruleus cells in guinea pig brain slices (IC50 = 7 nM). Exhibits anxiolytic and antidepressant-like effects. Active in vivo.
CP 122721 hydrochloride is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
M. Wt | 453.33 |
Formula | C20H23F3N2O2.2HCl |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 145877-52-7 |
PubChem ID | 90664465 |
InChI Key | AVTRGAPFNJEOTQ-FFUVTKDNSA-N |
Smiles | Cl.Cl.COC1=C(CN[C@H]2CCCN[C@H]2C2=CC=CC=C2)C=C(OC(F)(F)F)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 45.33 | 100 | |
DMSO | 45.33 | 100 |
The following data is based on the product molecular weight 453.33. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.21 mL | 11.03 mL | 22.06 mL |
5 mM | 0.44 mL | 2.21 mL | 4.41 mL |
10 mM | 0.22 mL | 1.1 mL | 2.21 mL |
50 mM | 0.04 mL | 0.22 mL | 0.44 mL |
References are publications that support the biological activity of the product.
McLean et al (1996) Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. J.Pharmacol.Exp.Ther. 277 900 PMID: 8627572
Gonsalves et al (1996) Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur.J.Pharmacol. 305 181 PMID: 8813551
Auais et al (2003) Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. Am.J.Physiol. Lung Cell Mol.Physiol. 285 L105 PMID: 12639840
If you know of a relevant reference for CP 122721 hydrochloride, please let us know.
Keywords: CP 122721 hydrochloride, CP 122721 hydrochloride supplier, CP122721, hydrochloride, 145742-28-5, K1, antagonists, antagonism, tachykinin, receptors, neurokinin, 1, NK1, substance, P, SP, depression, emesis, inflammatory, diseases, asthma, irritable, bowel, syndrome, antiemetics, IBS, Receptor, 3649, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for CP 122721 hydrochloride. Do you know of a great paper that uses CP 122721 hydrochloride from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review CP 122721 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.